UNICA IRIS Institutional Research Information System

PUZZONI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 60.300
NA - Nord America 3.599
AS - Asia 1.960
SA - Sud America 300
Continente sconosciuto - Info sul continente non disponibili 194
AF - Africa 53
OC - Oceania 3
Totale 66.409
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 59.464
US - Stati Uniti d'America 3.497
SG - Singapore 861
CN - Cina 524
BR - Brasile 223
VN - Vietnam 222
SE - Svezia 205
DE - Germania 125
FR - Francia 100
FI - Finlandia 82
GB - Regno Unito 80
HK - Hong Kong 71
IN - India 68
UA - Ucraina 66
CA - Canada 59
NL - Olanda 48
BD - Bangladesh 31
KR - Corea 24
MX - Messico 23
AR - Argentina 21
JP - Giappone 21
PL - Polonia 21
AT - Austria 20
IQ - Iraq 20
ES - Italia 18
TR - Turchia 18
ZA - Sudafrica 17
EC - Ecuador 16
CO - Colombia 15
ID - Indonesia 14
PK - Pakistan 14
IE - Irlanda 13
VE - Venezuela 12
MA - Marocco 11
RU - Federazione Russa 11
BE - Belgio 9
PH - Filippine 8
AE - Emirati Arabi Uniti 7
IR - Iran 7
KG - Kirghizistan 7
UZ - Uzbekistan 7
SA - Arabia Saudita 6
TN - Tunisia 6
IL - Israele 5
TH - Thailandia 5
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
EG - Egitto 4
JM - Giamaica 4
KE - Kenya 4
MK - Macedonia 4
PE - Perù 4
AU - Australia 3
GR - Grecia 3
LT - Lituania 3
LV - Lettonia 3
NP - Nepal 3
PY - Paraguay 3
RS - Serbia 3
AL - Albania 2
AM - Armenia 2
BB - Barbados 2
BO - Bolivia 2
CH - Svizzera 2
DM - Dominica 2
DZ - Algeria 2
HU - Ungheria 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
BH - Bahrain 1
BZ - Belize 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MN - Mongolia 1
MT - Malta 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 66.212
Salva come PNG Salva come JPEG
Città #
Cagliari 57.554
Uta 1.551
Singapore 508
Ashburn 403
Dallas 297
San Jose 268
Fairfield 245
Boardman 155
Woodbridge 133
Nyköping 129
Houston 127
Beijing 113
Seattle 112
Chandler 111
Council Bluffs 104
Los Angeles 94
Cambridge 87
Wilmington 77
Dearborn 69
New York 68
Ho Chi Minh City 66
Santa Clara 64
Hong Kong 62
Helsinki 56
The Dalles 53
Ann Arbor 51
Rome 43
Hanoi 42
Shanghai 39
Lauterbourg 38
Boston 37
Orem 31
Jacksonville 30
Chicago 28
Dong Ket 28
Buffalo 27
Amsterdam 26
Frankfurt am Main 25
Hefei 25
Munich 25
São Paulo 25
Nanjing 23
Seoul 23
London 21
Milan 21
Columbus 19
Redondo Beach 19
San Diego 19
Guangzhou 18
Nuremberg 18
Toronto 17
Warsaw 17
Montreal 15
Paris 15
Phoenix 15
Pune 14
Shenyang 13
Tokyo 13
Atlanta 12
Düsseldorf 12
Hangzhou 12
Turku 12
Brooklyn 11
Chennai 11
Poplar 11
Zhengzhou 11
Dublin 10
Naples 9
Stockholm 9
Tianjin 9
Vienna 9
Changsha 8
Da Nang 8
Haiphong 8
Mont-saint-hilaire 8
Rio de Janeiro 8
Shenzhen 8
Wuhan 8
Augusta 7
Baghdad 7
Bishkek 7
Casablanca 7
Jiaxing 7
Johannesburg 7
Medellín 7
Mumbai 7
Salt Lake City 7
Tashkent 7
Belo Horizonte 6
Biên Hòa 6
Buenos Aires 6
Charlotte 6
Denver 6
Hải Dương 6
Nanchang 6
New Delhi 6
Quito 6
Redwood City 6
Selargius 6
Bexley 5
Totale 63.661
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.186
Clustered protocadherins methylation alterations in cancer 3.338
BRAF-mutant colorectal cancer, a different breed evolving 3.248
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.988
Molecular-biology-driven treatment for metastatic colorectal cancer 2.779
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.711
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.644
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.461
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.383
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.342
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.146
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 2.127
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.981
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.698
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.637
Immunotherapy and Cancer: The Multi-Omics Perspective 1.627
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.547
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.420
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.372
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.346
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.301
Immunotherapy for colorectal cancer: where are we heading? 1.279
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.271
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.226
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 1.096
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.095
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 1.020
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 998
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 967
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 964
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 885
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 780
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? 761
Cholangiocarcinoma: new perspectives for new horizons 735
Uncovering key targets of success for immunotherapy in pancreatic cancer 730
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 613
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study 512
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon 444
Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-RAS and N-RAS wild type metastatic colorectal cancer (SUPER-PEAK) 352
CD44: A New Prognostic Marker in Colorectal Cancer? 278
A new prognostic score for biliary tract cancer: a multicenter experience 231
REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol) 227
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 219
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 212
Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment 208
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions 193
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience 193
Medical management of malignant bowel obstruction: our center experience 191
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 178
LONG-TERM RESPONSE TO SUNITINIB, EVEROLIMUS AND AXITINIB SEQUENTIALLY USED IN A YOUNG WOMEN WITH MRCC. A CASE REPORT 150
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer 145
Preoperatory FLOT Regimen for Gastroesophageal Cancer and Renal Function: A New Onco-Nephrological Perspective 141
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 129
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study 126
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 122
The correlation between L1CAM expression and outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy 121
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 113
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 111
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 111
Totale 66.409
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.675
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.675
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.922 0 193 156 245 212 210 192 221 297 365 335 496
2022/20235.508 509 934 730 402 390 440 230 413 343 500 378 239
2023/20247.333 338 205 187 345 509 854 854 2.301 271 372 562 535
2024/202514.465 4.177 4.456 1.416 1.341 691 965 752 66 159 132 110 200
2025/20265.051 382 281 470 432 376 357 1.055 447 310 469 286 186
2026/2027241 80 161 0 0 0 0 0 0 0 0 0 0
Totale 66.409